CB2 Receptor Agonists for Selective Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic applications of cannabinoids are limited by their psychoactive effects, and there is a need for compounds that can selectively modulate the CB2 receptor to treat inflammation and pain without affecting the central nervous system.
Innovation Solution
Development of novel compounds that bind to and modulate the CB2 receptor, acting as CB2 agonists to treat inflammation and pain by administering therapeutic amounts, thereby avoiding the psychoactive effects associated with CB1 receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are used for therapeutic applications, then anti-inflammatory and analgesic effects are achieved, but psychoactive side effects occur due to CB1 receptor activation
Solution Approach 1:
The invention segments the cannabinoid receptor system by developing compounds that selectively target only the CB2 receptor subtype, separating the therapeutic effects (mediated by CB2) from the psychoactive effects (mediated by CB1). This selectivity allows independent modulation of immune functions without affecting central nervous system cannabinoid receptors.
Solution Approach 2:
The invention applies local quality by designing molecules with specific structural characteristics that confer preferential binding affinity for CB2 receptors over CB1 receptors. The compounds possess molecular features (such as specific substituent patterns on the core structure) that match the binding pocket characteristics of CB2, enabling location-specific action at peripheral immune cells while avoiding CNS penetration and CB1 activation.
2Adaptability or versatility
If CB1 receptor activation occurs, then central nervous system effects are produced, but therapeutic selectivity for immune system modulation is reduced
Solution Approach 1:
The invention segments the receptor targeting capability by creating a subset of cannabinoid compounds that exclusively interact with CB2 receptors. This segmentation divides the broad-spectrum cannabinoid activity into selective CB2-modulating agents, enabling precise targeting of immune system cannabinoid receptors while excluding central nervous system CB1 receptors from interaction.
Solution Approach 2:
The invention implements local quality through molecular design features that create preferential affinity for CB2 receptor binding sites. Specific structural modifications (such as particular substituent groups at defined positions on the core molecule) confer selective recognition by CB2 receptors, ensuring that the therapeutic agent acts locally at peripheral immune tissues without affecting distant CB1 receptors in the brain.
Data Source
AI summary
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.